Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 10
Submit an article Journal homepage
974
Views
58
CrossRef citations to date
0
Altmetric
Reviews

LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence

Richard A Rudick Director Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA +1 216 444 8603; +1 216 445 7013; [email protected]
, MD,
Sha Mi Biogen Idec, Department of Discovery Neurobiology, Cambridge, MA, USA
, PhD &
Alfred W Sandrock Jr Biogen Idec, Department of Discovery Neurobiology, Cambridge, MA, USA
, MD PhD
Pages 1561-1570 | Published online: 07 Sep 2008

Citations (58)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Aatif M. Husain. (2018) Ellen Grass Memorial Lecture: Clinical Neurophysiology in the Treatment of Disease. The Neurodiagnostic Journal 58:4, pages 203-212.
Read now
Serena Ruggieri, Carla Tortorella & Claudio Gasperini. (2017) Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis. Expert Review of Neurotherapeutics 17:11, pages 1081-1089.
Read now
Catalina Coclitu, Cris S. Constantinescu & Radu Tanasescu. (2016) The future of multiple sclerosis treatments. Expert Review of Neurotherapeutics 16:12, pages 1341-1356.
Read now
Jessica Craddock & Silva Markovic-Plese. (2015) Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing. Expert Review of Clinical Pharmacology 8:3, pages 283-296.
Read now
Felix Luessi, Tanja Kuhlmann & Frauke Zipp. (2014) Remyelinating strategies in multiple sclerosis. Expert Review of Neurotherapeutics 14:11, pages 1315-1334.
Read now
Benjamin Knier, Bernhard Hemmer & Thomas Korn. (2014) Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opinion on Biological Therapy 14:4, pages 503-513.
Read now
Paulo Fontoura. (2010) Monoclonal antibody therapy in multiple sclerosis. mAbs 2:6, pages 670-681.
Read now

Articles from other publishers (51)

Avik Atta, Ayushi Gupta, Princy Choudhary, Shrey Dwivedi & Sangeeta Singh. (2023) Inhibition of LINGO1 as a therapeutic target to promote axonal regeneration and repair for neurological disorders. 3 Biotech 13:11.
Crossref
Ghufran Lutfi Ismaeel, Olfet Jabbar Makki AlHassani, Reem S. Alazragi, Ammar Hussein Ahmed, Asma'a H. Mohamed, Nisreen Yasir Jasim, Falah Hassan Shari & Haider Abdulkareem Almashhadani. (2023) Genetically engineered neural stem cells ( NSCs ) therapy for neurological diseases; state‐of‐the‐art . Biotechnology Progress 39:5.
Crossref
Midhuna Devanand, Saiprabha V.N.Krishnadas Madhu. (2023) Signaling mechanisms involved in the regulation of remyelination in multiple sclerosis: a mini review. Journal of Molecular Medicine 101:6, pages 637-644.
Crossref
Ilias Kalafatakis, Fevronia Papagianni, Konstantinos Theodorakis & Domna Karagogeos. (2023) Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration. International Journal of Molecular Sciences 24:5, pages 4479.
Crossref
Najam A. Sharif. 2023. Translational Neuroimmunology, Volume 7. Translational Neuroimmunology, Volume 7 287 329 .
Marjan Gharagozloo, Riley Bannon & Peter A. Calabresi. (2022) Breaking the barriers to remyelination in multiple sclerosis. Current Opinion in Pharmacology 63, pages 102194.
Crossref
Joachim Havla & Reinhard Hohlfeld. (2022) Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. Neurotherapeutics 19:3, pages 774-784.
Crossref
Fabien Binamé, Lucas D. Pham-Van & Dominique Bagnard. (2021) Manipulating oligodendrocyte intrinsic regeneration mechanism to promote remyelination. Cellular and Molecular Life Sciences 78:13, pages 5257-5273.
Crossref
Denise D Correa, Jaya Satagopan, Axel Martin, Erica Braun, Maria Kryza-Lacombe, Kenneth Cheung, Ajay Sharma, Sofia Dimitriadoy, Kelli O’Connell, Siok Leong, Sasan Karimi, John Lyo, Lisa M DeAngelis & Irene Orlow. (2019) Genetic variants and cognitive functions in patients with brain tumors. Neuro-Oncology 21:10, pages 1297-1309.
Crossref
Marina Pöttler, Iwona Cicha, Harald Unterweger, Christina Janko, Ralf P Friedrich & Christoph Alexiou. (2019) Nanoparticles for regenerative medicine. Nanomedicine 14:15, pages 1929-1933.
Crossref
George G. Bastakis, Niki Ktena, Domna Karagogeos & Maria Savvaki. (2019) Models and treatments for traumatic optic neuropathy and demyelinating optic neuritis. Developmental Neurobiology 79:8, pages 819-836.
Crossref
Forouzan Yousefi, Fahimeh Lavi Arab, Kolsoum Saeidi, Houshang Amiri & Mahmoud Mahmoudi. (2019) Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: Focus on mesenchymal stem cells and neuroprotection. Journal of Neuroimmunology 328, pages 20-34.
Crossref
Mehrdad Gholamzad, Masoumeh Ebtekar, Mehdi Shafiee Ardestani, Maryam Azimi, Zeinab Mahmodi, Mohammad Javad Mousavi & Saeed Aslani. (2018) A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflammation Research 68:1, pages 25-38.
Crossref
Yuki Fujita & Toshihide Yamashita. 2019. Neuroimmune Diseases. Neuroimmune Diseases 63 81 .
Charlotte G H M de Jong, Mirjana Stancic, Tineke H Pinxterhuis, Jack van Horssen, Anne-Marie van Dam, Hans-Joachim Gabius & Wia Baron. (2018) Galectin-4, a Negative Regulator of Oligodendrocyte Differentiation, Is Persistently Present in Axons and Microglia/Macrophages in Multiple Sclerosis Lesions. Journal of Neuropathology & Experimental Neurology 77:11, pages 1024-1038.
Crossref
Oliver Findling, Heiko Rust, Özgür Yaldizli, Dionne P. H. Timmermans, Alja Scheltinga & John H. J. Allum. (2018) Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases. Frontiers in Neurology 9.
Crossref
AdrianaOctaviana Dulamea. (2017) The contribution of oligodendrocytes and oligodendrocyte progenitor cells to central nervous system repair in multiple sclerosis: perspectives for remyelination therapeutic strategies. Neural Regeneration Research 12:12, pages 1939.
Crossref
Manuela Cerina, Venu Narayanan, Kerstin Göbel, Stefan Bittner, Tobias Ruck, Patrick Meuth, Alexander M. Herrmann, Martin Stangel, Viktoria Gudi, Thomas Skripuletz, Thiemo Daldrup, Heinz Wiendl, Thomas Seidenbecher, Petra Ehling, Christoph Kleinschnitz, Hans-Christian Pape, Thomas Budde & Sven G. Meuth. (2017) The quality of cortical network function recovery depends on localization and degree of axonal demyelination. Brain, Behavior, and Immunity 59, pages 103-117.
Crossref
Adriana Octaviana Dulamea. 2017. Multiple Sclerosis: Bench to Bedside. Multiple Sclerosis: Bench to Bedside 91 127 .
Kelly A. Chamberlain, Sonia E. Nanescu, Konstantina Psachoulia & Jeffrey K. Huang. (2016) Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis. Neuropharmacology 110, pages 633-643.
Crossref
Emanuele D’Amico, Francesco Patti, Aurora Zanghì & Mario Zappia. (2016) A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. International Journal of Molecular Sciences 17:10, pages 1725.
Crossref
Natalie A. Wheeler & Babette Fuss. (2016) Extracellular cues influencing oligodendrocyte differentiation and (re)myelination. Experimental Neurology 283, pages 512-530.
Crossref
Afsaneh Shirani, Darin T. Okuda & Olaf Stüve. (2016) Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. Neurotherapeutics 13:1, pages 58-69.
Crossref
Helmut Wilhelm & Martin Schabet. (2015) The Diagnosis and Treatment of Optic Neuritis. Deutsches Ärzteblatt international.
Crossref
Chenyu Wang, David Paling, Luke Chen, Sean N Hatton, Jim Lagopoulos, Swee T Aw, Matthew C Kiernan & Michael H Barnett. (2014) Axonal conduction in multiple sclerosis: A combined magnetic resonance imaging and electrophysiological study of the medial longitudinal fasciculus. Multiple Sclerosis Journal 21:7, pages 905-915.
Crossref
Yongjie Zhang, Yi Ping Zhang, Blake Pepinsky, Guanrong Huang, Lisa B.E. Shields, Christopher B. Shields & Sha Mi. (2015) Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination. Experimental Neurology 266, pages 68-73.
Crossref
Ekaterina Kotelnikova, Marti Bernardo-Faura, Gilad Silberberg, Narsis A Kiani, Dimitris Messinis, Ioannis N Melas, Laura Artigas, Elena Schwartz, Ilya Mazo, Mar Masso, Leonidas G Alexopoulos, Jose Manuel Mas, Tomas Olsson, Jesper Tegner, Roland Martin, Albert Zamora, Friedemann Paul, Julio Saez-Rodriguez & Pablo Villoslada. (2014) Signaling networks in MS: A systems-based approach to developing new pharmacological therapies. Multiple Sclerosis Journal 21:2, pages 138-146.
Crossref
L Cobret, M L De Tauzia, J Ferent, E Traiffort, I Hénaoui, F Godin, E Kellenberger, D Rognan, J Pantel, H Bénédetti & S Morisset-Lopez. (2015) Targeting the cis -dimerization of LINGO-1 with low MW compounds affects its downstream signalling . British Journal of Pharmacology 172:3, pages 841-856.
Crossref
Pavan Bhargava, Andrew Lang, Omar Al-Louzi, Aaron Carass, Jerry Prince, Peter A. Calabresi & Shiv Saidha. (2015) Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials. Multiple Sclerosis International 2015, pages 1-10.
Crossref
Jonathan Q. TranJitesh RanaFrederik BarkhofIsaac MelamedHakop GevorkyanMike P. WattjesRemko de JongKristin BrosofskySoma RayLei XuJim ZhaoEdward ParrDiego Cadavid. (2014) Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurology Neuroimmunology & Neuroinflammation 1:2.
Crossref
Martin E Schwab & Stephen M Strittmatter. (2014) Nogo limits neural plasticity and recovery from injury. Current Opinion in Neurobiology 27, pages 53-60.
Crossref
F Fernandez-Enright, J L Andrews, K A Newell, C Pantelis & X F Huang. (2014) Novel implications of Lingo-1 and its signaling partners in schizophrenia. Translational Psychiatry 4:1, pages e348-e348.
Crossref
Malene Winther & Peter S. Walmod. 2014. Cell Adhesion Molecules. Cell Adhesion Molecules 315 395 .
Giancarlo Comi. (2013) Disease-modifying treatments for progressive multiple sclerosis. Multiple Sclerosis Journal 19:11, pages 1428-1436.
Crossref
Marcus W. Koch, Gary Cutter, Peter K. Stys, V. Wee Yong & Luanne M. Metz. (2013) Treatment trials in progressive MS—current challenges and future directions. Nature Reviews Neurology 9:9, pages 496-503.
Crossref
Maria Podbielska, Naren Banik, Ewa Kurowska & Edward Hogan. (2013) Myelin Recovery in Multiple Sclerosis: The Challenge of Remyelination. Brain Sciences 3:4, pages 1282-1324.
Crossref
Sha Mi, R. Blake Pepinsky & Diego Cadavid. (2013) Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the Clinic. CNS Drugs 27:7, pages 493-503.
Crossref
Li He & Q. Richard Lu. (2013) Coordinated control of oligodendrocyte development by extrinsic and intrinsic signaling cues. Neuroscience Bulletin 29:2, pages 129-143.
Crossref
Hong-Fu Wu, Jing-Sheng Cen, Qian Zhong, Luming Chen, Jue Wang, David Y.B. Deng & Yong Wan. (2013) The promotion of functional recovery and nerve regeneration after spinal cord injury by lentiviral vectors encoding Lingo-1 shRNA delivered by Pluronic F-127. Biomaterials 34:6, pages 1686-1700.
Crossref
Foroozan Mokhtarian, Farinaz Safavi & Ehsan Sarafraz-Yazdi. (2012) Immunization with a peptide of Semliki Forest virus promotes remyelination in experimental autoimmune encephalomyelitis. Brain Research 1488, pages 92-103.
Crossref
Robin J. M. Franklin, Charles ffrench-Constant, Julia M. Edgar & Kenneth J. Smith. (2012) Neuroprotection and repair in multiple sclerosis. Nature Reviews Neurology 8:11, pages 624-634.
Crossref
Ilana B Katz Sand & Stephen Krieger. (2012) Emerging strategies for the treatment of multiple sclerosis. Future Neurology 7:2, pages 193-207.
Crossref
Camilla Lööv, Maria Fernqvist, Adrian Walmsley, Niklas Marklund & Anna Erlandsson. (2012) Neutralization of LINGO-1 during In Vitro Differentiation of Neural Stem Cells Results in Proliferation of Immature Neurons. PLoS ONE 7:1, pages e29771.
Crossref
H. Deng, S. Gu & J. Jankovic. (2012) LINGO1 variants in essential tremor and Parkinson’s disease. Acta Neurologica Scandinavica 125:1, pages 1-7.
Crossref
Jeffrey K. Huang & Robin J.M. Franklin. 2012. Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part II. Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part II 219 231 .
Sarwat Chowdhury, E. Hampton Sessions, Jennifer R. Pocas, Wayne Grant, Thomas Schröter, Li Lin, Claudia Ruiz, Michael D. Cameron, Stephan Schürer, Philip LoGrasso, Thomas D. Bannister & Yangbo Feng. (2011) Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I). Bioorganic & Medicinal Chemistry Letters 21:23, pages 7107-7112.
Crossref
Anna Rosell, Anna Vilalta, Teresa García-Berrocoso, Israel Fernández-Cadenas, Sophie Domingues-Montanari, Eloy Cuadrado, Pilar Delgado, Marc Ribó, Elena Martínez-Sáez, Arantxa Ortega-Aznar & Joan Montaner. (2011) Brain Perihematoma Genomic Profile Following Spontaneous Human Intracerebral Hemorrhage. PLoS ONE 6:2, pages e16750.
Crossref
Eilhard Mix, Hans Meyer-Rienecker, Hans-Peter Hartung & Uwe K. Zettl. (2010) Animal models of multiple sclerosis—Potentials and limitations. Progress in Neurobiology 92:3, pages 386-404.
Crossref
Gabrièle Piaton, Robert M. Gould & Catherine Lubetzki. (2010) Axon‐oligodendrocyte interactions during developmental myelination, demyelination and repair. Journal of Neurochemistry 114:5, pages 1243-1260.
Crossref
Stephen P.J. Fancy, Mark R. Kotter, Emily P. Harrington, Jeffrey K. Huang, Chao Zhao, David H. Rowitch & Robin J.M. Franklin. (2010) Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Experimental Neurology 225:1, pages 18-23.
Crossref
E. Hampton Sessions, Michael Smolinski, Bo Wang, Bozena Frackowiak, Sarwat Chowdhury, Yan Yin, Yen Ting Chen, Claudia Ruiz, Li Lin, Jennifer Pocas, Thomas Schröter, Michael D. Cameron, Philip LoGrasso, Yangbo Feng & Thomas D. Bannister. (2010) The development of benzimidazoles as selective rho kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 20:6, pages 1939-1943.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.